At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OPTN Optinose Inc.
Halted 05-20 16:00:00 EDT
9.60
+0.00
0.00%
High9.60
Low9.60
Vol0.00
Open9.60
D1 Closing9.60
Amplitude0.00%
Mkt Cap97.22M
Tradable Cap60.64M
Total Shares10.13M
T/O7.77M
T/O Rate0.00%
Tradable Shares6.32M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Paratek Pharmaceuticals Completes Acquisition of Optinose, Expands Specialty Therapies Portfolio
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.